Bright Minds Biosciences Inc. (DRUG) stock
DRUGNasdaqPharmaceutical PreparationsFiscal year ends September 30
$20.40−0.30 (-1.45%)
Close on Nov 20, 2026Market cap $155.77MP/E –Yield –
Bright Minds Biosciences revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
No revenue figures for Bright Minds Biosciences
Bright Minds Biosciences has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?